NVO · earnings call history
Novo Nordisk FY25 — Strong GLP-1 Growth and Wegovy Pill Launch Amidst 2026 Pricing Headwinds
Read the briefNovo Nordisk Q3 FY25 — Strategic Refocus and Pipeline Expansion Amidst Competitive Headwinds
Read the briefNovo Nordisk Q2 FY25 — Strong H1 GLP-1 Growth Tempered by Revised Full-Year Outlook
Read the briefBrowse all US companies on the earnings-call register.